RxDoctor Payments Data

Shelli-Marie Nelson, APRN

Family · Santa Barbara, CANPI 1093040354

Payments from drug & device makers

$1,292in general payments, 2019–2025

Across 60 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$258
  • AstraZeneca$171
  • Regeneron Healthcare Solutions, Inc.$127
  • Novartis$126
  • Pfizer$123
  • Takeda Pharmaceuticals U.S.A., Inc.$83
  • plus $403 from 12 others

What the payments were for

  • Consulting fees$403%
  • Food & beverage$1,25297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,292 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$21,466
Medicare patients
218
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$21,199
Advair HfaFluticasone Propion/Salmeterol35$12,448
Arnuity ElliptaFluticasone Furoate19$7,132
Breo ElliptaFluticasone/Vilanterol18$7,087
SymbicortBudesonide/Formoterol Fumarate16$4,047
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,490
Azelastine Hcl63$1,396
Montelukast Sodium77$1,353
Ipratropium Bromide40$1,120
Fluticasone Propionate51$917
Albuterol Sulfate HfaAlbuterol Sulfate32$858
Levocetirizine Dihydrochloride18$324
Omeprazole23$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta$258$35,41861 claims
AstraZenecaSymbicort$171$4,04716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →